Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes. This study evaluated the TLRs 7/8 agonist, Resiquimod® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Pyrimethamine ® & Sulphadiazine®. This was judged by the number of brain cysts, the histpathological degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls. The results showed a statistically significant decrease in the number of brain cysts in resiquimod- treated mice correlated with the histopathological improvement of brain and retina and apoptosis.
BRAKAT, R., BADR, N., SOLIMAN, S., & SHARAF-EL-DEEN, S. (2023). THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE. Journal of the Egyptian Society of Parasitology, 53(3), 537-546. doi: 10.21608/jesp.2023.331739
MLA
REHAM M. BRAKAT; NAHLA M. BADR; SHAIMAA S. SOLIMAN; SHAIMAA A. SHARAF-EL-DEEN. "THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE". Journal of the Egyptian Society of Parasitology, 53, 3, 2023, 537-546. doi: 10.21608/jesp.2023.331739
HARVARD
BRAKAT, R., BADR, N., SOLIMAN, S., SHARAF-EL-DEEN, S. (2023). 'THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE', Journal of the Egyptian Society of Parasitology, 53(3), pp. 537-546. doi: 10.21608/jesp.2023.331739
VANCOUVER
BRAKAT, R., BADR, N., SOLIMAN, S., SHARAF-EL-DEEN, S. THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE. Journal of the Egyptian Society of Parasitology, 2023; 53(3): 537-546. doi: 10.21608/jesp.2023.331739